Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HINT1 | P49773 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ADA | P00813 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31011272 | 0.91 | HPGD (0.50) | HPGDHINT1ADORA2AADORA3NT5E | |
| SCHEMBL23883607 | 0.90 | HPGD (0.50) | HPGDHINT1ADORA2AADORA3NT5E | |
| SCHEMBL6863967 | 0.90 | HPGD (0.50) | HPGDHINT1ADORA2AADORA3NT5E | |
| SCHEMBL6512797 | 0.89 | HPGD (0.48) | HPGDHINT1ADORA2AADORA3NT5E | |
| SCHEMBL31587707 | 0.88 | HINT1 (0.48) | HPGDHINT1ADORA3NT5EGSK3A | |
| SCHEMBL6515281 | 0.88 | HPGD (0.47) | HPGDHINT1ADORA2AADORA3NT5E | |
| SCHEMBL843560 | 0.87 | NT5E (0.56) | HINT1NT5EPOLBTGM2 | |
| 2'-B-Methyl-Guanosine SCHEMBL21007207 | 0.87 | ADORA2A (0.65) | HPGDHINT1ADORA2AADORA3NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL14853673 | 0.87 | ADORA2A (0.65) | HPGDHINT1ADORA2AADORA3NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL10819905 | 0.87 | ADORA2A (0.65) | HPGDHINT1ADORA2AADORA3NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747386-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | Bisirna Therapeutics Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025021034-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | VISIRNA THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2025-01-30 | — | — | WO | disclosed |
| US-12016875-B2 | Methods for treating or preventing ophthalmological conditions | IVERIC BIO, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4374873-A2 | METHODS FOR TREATING OR PREVENTING OPTHALMOLOGICAL CONDITIONS | IVERIC bio, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117362374-A | Method for protecting hydroxyl and amino in compound containing hydroxyl and amino | 天津兴博润生物制药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230364122-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IVERIC BIO, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364123-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IVERIC BIO, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20220175813-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IVERIC BIO, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210369757-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IVERIC BIO, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3628373-A1 | METHODS FOR TREATING OR PREVENTING OPTHALMOLOGICAL CONDITIONS | IVERIC bio, Inc. (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20150182623-A1 | Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist | Integrity Bio, Inc. | 2015-07-02 | — | — | US | disclosed |
| US-20150157709-A1 | Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist | Integrity Bio, Inc. | 2015-06-11 | — | — | US | disclosed |
| EP-2854844-A2 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | Ophthotech Corporation (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2015006734-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | OPHTHOTECH CORPORATION (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140179621-A1 | Methods for Treating or Preventing Ophthalmological Diseases | OPHTHOTECH CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013181495-A2 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | OPHTHOTECH CORPORATION (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130323242-A1 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | OPHTHOTECH CORP. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120100136-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2432476-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010127029-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179621-A1 | Methods for Treating or Preventing Ophthalmological Diseases | VEGFA, PDGFA, PGF | HPGD 457/4885HINT1 4290/4885ADORA2A 522/4885 |
| US-20210369757-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885ADORA2A 181/4885 |
| US-20220175813-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885ADORA2A 181/4885 |
| US-12016875-B2 | Methods for treating or preventing ophthalmological conditions | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885ADORA2A 181/4885 |
| US-20230364122-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IL5, HDAC5, MC5R | HPGD 613/4885HINT1 3370/4885ADORA2A 485/4885 |
| US-20230364123-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885ADORA2A 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.